Log in

Overcoming Challenges Starting A Life Science Company

  • 17 Apr 2014
  • 6:30 PM - 9:00 PM
  • Microsoft Technology Center, One Cambridge Center, Cambridge, MA. 02142


Registration is closed

FREE EVENT!  Join us as we listen to our fellow inhabitants of this life science ecosystem, as they share their own experiences as entrepreneurs and investors. Our panelists will shed light on strategies about capital raising, strategic licensing, creating strategic alliances and the many commercial considerations.



Pravin R. Chaturvedi, Ph.D., CEO, IndUS Pharmaceuticals, http://www.induspharm.com/  


Dr. Chaturvedi currently maintains multiple roles as the Chief Executive Officer of Boston-based IndUS Pharmaceuticals and Florida-based Oceanyx Pharmaceuticals. He is also the Chief Scientific Officer of San Francisco-based Napo Pharmaceuticals. He is a serial entrepreneur and has been the founder or co-founder of Oceanyx, IndUS and Scion Pharmaceuticals. Dr. Chaturvedi has served or currently remains on the boards of Scion, TiE Boston, IndUS, Sindu, Oceanyx, FuelEd and Cellanyx. He also serves as an advisory board member to TFC Biosciences and is the Chair of the Research Advisory Council for the Health Sciences Center of West Virginia University. He is also serves as an adjunct faculty member at Georgetown Medical School.

 Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or development activities for several new chemical entities (NCEs), culminating in the successful development and commercialization of seven new drugs that are currently marketed by various companies. Prior to founding Oceanyx, IndUS and Scion Pharmaceuticals, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation. Prior to Vertex, he was in the preclinical group at Alkermes and he started his R&D career in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer). Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.


Imran Nassarullah, M.S, J.D, C.L.P.,https://unitio.org/pages/t1d-exchange/


Imran is the founder of Europa Life Science Advisors, a business development and strategy consulting service for life sciences.  Formerly, Imran was Head of Strategic Alliances for T1D Exchange where he led business development and strategic alliances. He brings over 20 years of business development, IP and licensing experience crossing both corporate and academic spheres. He brings a rich synthesis of life sciences corporate development (emerging and early stage), intellectual property and licensing, and policy experience. Prior to joining T1D Exchange, Imran was the Chief Business Officer for the Massachusetts Biotechnology Council, where he was responsible for building MassBio's business development and investor outreach programs to enable members companies raise capital and identify strategic partnering and licensing opportunities. Prior to MassBio, Imran worked for Genzyme Genetics, a wholly owned subsidiary of Genzyme Corporation focused on molecular diagnostics. Imran served as a Director of Business Development and Licensing for oncology and women’s health. Previous to working at Genzyme, Imran worked for Millennium Pharmaceuticals as a Director of BD&L within Millennium Corporate Development. While there, Imran focused on Millennium’s R&D platform, Inflammation and Oncology franchises, and Velcade. Earlier in Imran’s career, he served as a director of licensing for the Dana Farber Cancer Institute and the Mayo Clinic.



Lisa Sasso, MBA, CPCC, ACC, Founder, Medical Development Partners, LLC


Lisa Sasso (http://meddevpartners.com/) is the Founder and President of Medical Development Partners, LLC (MDP). Prior to MDP, Lisa was the co-founder of Radi Medical Systems, Inc., a high tech medical device distributor specializing in innovative cardiology products. During her six-year tenure as President/CEO, she grew the company from inception to revenues of $28M with profitability. Lisa’s vision and strategic direction were responsible for the company’s explosive annual triple digit growth. Lisa built a seasoned Medical Device sales force with more than 550 years of combined sales experience. Motivated by excitement for new technologies, she built strong physician advisory boards and a seasoned clinical/sales team. Lisa and her team ultimately helped healthcare professionals make more informed treatment decisions resulting in better patient care. Lisa was recognized for her efforts and ranked #28 out of 100 Women Led Businesses in Massachusetts in 2004.

 As the founder of Medical Development Partners, she is passionate about helping entrepreneurial medical “start-ups start up”. With a focus on business planning and execution, she brings strategic thinking to both clients and their companies. Her vision and values have been instrumental in helping international companies successfully commercialize products in the United States.

 Lisa is the past President of Medical Development Group of Boston and has served on the Board Of Directors for 9 years. Lisa served on the Board of Scitent, a medical education and training company for 5 years. She is a member of the International Coach Federation (ICF) where she received her Associate Certified Coach (ACC) certification and is an active marketing and planning committee member. Finally, Lisa also speaks professionally to motivate and inspire individuals. Organizations and company professionals learn how to be the best that they can be and also how to achieve what they want both personally and professionally.


Ankit Mahadevia, MD, Venture Partner, Atlas Venture, http://www.atlasventure.com

Ankit Mahadevia is the Acting President and CBO of Spero Therapeutics. He is also a Venture Partner  in the life sciences group at Atlas Venture, located in Cambridge, MA, where he focuses on novel drug discovery platforms, therapeutic products, and other medical technologies that meet a significant unmet clinical need.

Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics.  He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals.  Previously, he worked in the health care groups of McKinsey & Company and Monitor Group.  Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS). He currently serves on the boards of Atlas companies Annovation Biopharma, RaNA Therapeutics, Lumavita, and Fibrex Medical.  He also works closely with Arteaus Therapeutics, JenaValve, and Nimbus Discovery and previously worked with Sirion Therapeutics (acquired by Alcon and Bausch & Lomb).  Ankit is also actively involved in the Shire/Atlas Venture Alliance and the Atlas/Monsanto Seed Fund Alliance.

 Ankit received an MD from the Johns Hopkins University School of Medicine and an MBA from the Wharton School of the University of Pennsylvania.  He received a BA in economics and biology, with honors, from Northwestern University, where he graduated summa cum laude. He was appointed by the U.S. Secretary of Health and Human Services to the Advisory Council of the NIH Center for Advancing Translational Sciences.   He also serves on board of the Johns Hopkins Alliance for Technology Transfer, through which he promotes translation of biomedical research by biotechnology companies. Ankit lives in Brookline, Massachusetts with his wife and two sons.




Praveen Bansal, M.S, CEO, TFC BioSciences


Praveen Bansal (http://www.tfcbio.com/) is the Founder and CEO of TFC BioSciences, Inc., a Worcester-based life sciences company with a mission to develop and commercialize smart tools for Drug Discovery. Prior to founding TFC BioSciences, she served as the Program Manager for the ADME/Tox market segment at Tecan, Inc., responsible for the development and global commercialization of fully validated, automated ADME/Tox platform solutions to market. She also held multiple positions at Millennium Pharmaceuticals in drug discovery and development. Prior to Millennium, she was involved with oncology target research at ImmunoGen.

 She received her M.S. in Immunology and Preventive Medicine from Iowa State University, an M.S. in Pharmaceutical Chemistry and a Bachelors in Pharmacy from College of Pharmacy, Indore, India